What are the symptoms and management of measles?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Measles Symptoms and Management

Measles is characterized by a prodrome of fever, cough, coryza (runny nose), and conjunctivitis followed by a maculopapular rash that begins on the face and spreads downward to the trunk and extremities, with potential for severe complications including pneumonia and encephalitis. 1

Clinical Presentation

Incubation and Prodromal Phase

  • Incubation period averages 10-12 days from exposure to prodrome and 14 days from exposure to rash (range: 7-18 days) 1
  • Prodromal symptoms include:
    • Fever (often high)
    • Cough
    • Coryza (runny nose)
    • Conjunctivitis ("pink eye") 1
  • Koplik spots (small white spots on a red background inside the mouth) appear during the prodrome and are considered pathognomonic for measles 1

Rash Phase

  • Characteristic rash typically appears 3-4 days after fever onset 2
  • Rash progression:
    • Begins on face and behind ears
    • Spreads downward to trunk and outward to extremities 1, 2
    • Maculopapular or morbilliform in appearance 1
  • Rash appearance coincides with peak symptom intensity 2

Common Complications

  • Diarrhea (most common complication) 1
  • Middle ear infection (otitis media) 1
  • Bronchopneumonia 1, 2
  • Encephalitis (occurs in approximately 1 per 1,000 cases) 1
  • Death (occurs in 1-2 per 1,000 reported cases in the United States) 1

High-Risk Populations

  • Infants and young children face higher mortality risk than older children 1
  • Adults also experience higher complication rates 1
  • Pregnant women may experience increased rates of premature labor, spontaneous abortion, and low birth weight infants 1
  • Immunocompromised individuals (particularly those with leukemias, lymphomas, or HIV) may develop severe, prolonged infection, sometimes without the typical rash 1

Management

Diagnosis

  • Clinical suspicion based on characteristic symptoms and rash pattern 3
  • Laboratory confirmation:
    • Serum immunoglobulin M (IgM) testing is most common 3
    • PCR testing of respiratory specimens or urine may also be used 4

Supportive Care

  • Hydration and antipyretics for fever management 2
  • Nutritional support, particularly in malnourished patients 1

Specific Treatments

  • Vitamin A supplementation:
    • All children with clinical measles should receive vitamin A 1
    • Children <12 months: 100,000 IU orally 1
    • Children ≥12 months: 200,000 IU orally 1
    • Repeat dose for children with complicated measles (pneumonia, otitis, croup, diarrhea with moderate/severe dehydration, or neurological problems) on day 2 1
    • Additional dose 1-4 weeks later for those with vitamin A deficiency eye symptoms 1

Management of Complications

  • Antibiotics for secondary bacterial infections (particularly pneumonia) 1, 2
  • Oral rehydration therapy for diarrhea 1
  • Hospitalization for severe complications (pneumonia, encephalitis) 2, 4

Infection Control

  • Isolation during contagious period (4 days before rash to 4 days after rash appears) 1
  • Airborne precautions in healthcare settings 3
  • Use of N-95 masks by healthcare workers 3

Prevention

  • Vaccination is the cornerstone of measles prevention 1, 4
  • MMR (measles-mumps-rubella) vaccine:
    • First dose at 12-15 months of age 1
    • Second dose at 4-6 years of age 1
  • Post-exposure prophylaxis:
    • MMR vaccine may provide protection if given within 72 hours of exposure 1
    • Immunoglobulin may be used for high-risk individuals who cannot receive the vaccine 3

Special Considerations

  • Undernutrition is NOT a contraindication for measles vaccination; it should be considered a strong indication for vaccination 1
  • Fever, respiratory tract infection, and diarrhea are not contraindications for measles vaccination 1
  • Unimmunized persons infected with HIV should receive the vaccine unless severely immunosuppressed 1

Prognosis

  • Case fatality rate in the United States: 1-2 per 1,000 reported cases 1
  • Case fatality rate in developing countries: can be as high as 25% 1
  • Long-term sequelae may include permanent brain damage from encephalitis 1
  • Subacute sclerosing panencephalitis (SSPE) is a rare but fatal late complication that appears years after infection 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Measles pneumonitis.

Advances in respiratory medicine, 2019

Research

An Update and Review of Measles for Emergency Physicians.

The Journal of emergency medicine, 2020

Research

Measles.

Lancet (London, England), 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.